Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05504382
Other study ID # P.T.REC/012/003788
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 1, 2022
Est. completion date May 1, 2023

Study information

Verified date August 2022
Source Egyptian Chinese University
Contact Alaa Anwar, Ph.D
Phone +201002538439
Email Aalaa.anwar222@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

the purpose of the study is to investigate the effect of Electrical Acupuncture Versus naproxen phonophoresis on Refractory pain in Juvenile Rheumatoid arthritis


Description:

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children and adolescents, affecting approximately one in 1000 children in North America. It is diagnosed in children younger than 16 years of age with arthritis in one or more joints for at least six weeks after other causes have been excluded. Arthritis in JIA is characterized by stiffness, pain and swelling of affected joints. The disease course of JIA may involve flares of increased disease activity or chronic persistent joint inflammation, even into adulthood. Various complications may arise secondary to ongoing disease activity or treatment, including joint damage and deformity, growth abnormalities and osteoporosis with fragility fractures The prevalence of refractory pain in children with arthritis is of particular concern because it often contributes to poor physical and psychosocial outcomes. Increased daily symptoms of pain predict considerable functional disability, including significantly reduced participation in school, social and physical activities, and augmented mood disturbance


Recruitment information / eligibility

Status Recruiting
Enrollment 42
Est. completion date May 1, 2023
Est. primary completion date November 1, 2022
Accepts healthy volunteers No
Gender All
Age group 14 Years to 16 Years
Eligibility Inclusion Criteria: - • Age ranges from 14 to 16 years. - All children will be assigned to the study are suffering from persistent oligoarthritis. - All children have regional knee pain complaint more than 6 weeks. - Pain and stiffness especially in the morning, and a joint that feels warm to the touch - Low grade fever at the onset of disease Exclusion Criteria: - • Neurological disorders. - Dermatological disorders. - Acute trauma prior to the study. - Other co- morbidities like diabetes and conditions associated with inflammation such as malegnancies. - Analgesic drugs or NSAIDs during the treatment period.

Study Design


Intervention

Device:
naproxen phonophoresis
transmission of naproxen molecule by therapeutic ultrasound

Locations

Country Name City State
Egypt Cairo University Cairo

Sponsors (1)

Lead Sponsor Collaborator
Mohamed Abdelmoneim El Meligy

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary knee pain change in refractory knee pain will be assessed by visual analogue scale 2 weeks
Secondary knee joint range of motion change in the range of motion of knee joint will be measured by universal goniometer 2 weeks
See also
  Status Clinical Trial Phase
Completed NCT00004420 - Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis N/A
Completed NCT00090571 - Juvenile Rheumatoid Arthritis Research Registry
Recruiting NCT05545839 - Transition to Adulthood Through Coaching and Empowerment in Rheumatology N/A
Completed NCT00010335 - Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders Phase 1
Completed NCT00690573 - Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis Phase 3
Completed NCT00443430 - Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis Phase 4
Completed NCT03780959 - Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA) Phase 2/Phase 3
Active, not recruiting NCT00006055 - Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases N/A
Completed NCT00570934 - Supplementation With Vitamin D, Calcium or Both on Calcium Absorption and Bone Mineral Content in Children With JRA Phase 3
Recruiting NCT05715463 - Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity N/A
Completed NCT00289094 - Randomized Fixed Bearing vs Mobile Bearing Cruciate Retaining TKA N/A
Terminated NCT00078806 - Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis Phase 3
Completed NCT00078793 - Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis N/A
Completed NCT00000429 - Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis Phase 2
Completed NCT01044823 - Use of Thermal and 3D Imaging to Quantify Arthritis N/A
Terminated NCT00029042 - Infliximab to Treat Children With Juvenile Rheumatoid Arthritis Phase 2
Withdrawn NCT00286689 - Effects of Growth Hormone in Chronically Ill Children N/A
Completed NCT00095173 - BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis Phase 3
Completed NCT00001862 - TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis Phase 2
Not yet recruiting NCT05114343 - Effectiveness and Feasibility of a Home-based Exercise Program for Adolescents With Juvenile Idiopathic Arthritis N/A